View Filing Data

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2018	Oct. 31, 2018
Document And Entity Information
Entity Registrant Name	Stereotaxis, Inc.
Entity Central Index Key	0001289340
Document Type	10-Q
Document Period End Date	Sep. 30, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		59,052,782
Trading Symbol	STXS
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2018

Balance Sheets - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 11,570,566	$ 3,686,302
Accounts receivable, net of allowance of $300,510 and $361,350 in 2018 and 2017, respectively	5,088,111	4,287,255
Inventories, net	1,202,457	1,146,971
Prepaid expenses and other current assets	970,397	750,085
Total current assets	18,831,531	9,870,613
Property and equipment, net	452,639	592,688
Intangible assets, net	109,979	159,470
Other assets	226,939	44,432
Total assets	19,621,088	10,667,203
Current liabilities:
Accounts payable	1,574,035	1,654,101
Accrued liabilities	2,822,958	3,195,247
Deferred revenue	6,365,676	5,702,769
Warrants		19,574,977
Total current liabilities	10,762,669	30,127,094
Long-term deferred revenue	502,893	611,863
Other liabilities	621,573	535,369
Total liabilities	11,887,135	31,274,326
Convertible Preferred stock:
Convertible Preferred stock, par value $0.001; 10,000,000 shares authorized, 23,900 shares outstanding at 2018 and 2017	5,960,475	5,960,475
Stockholders' equity (deficit):
Common stock, par value $0.001; 300,000,000 shares authorized, 59,044,164 and 22,805,731 shares issued at 2018 and 2017, respectively	59,044	22,806
Additional paid in capital	478,071,950	450,748,403
Treasury stock, 4,015 shares at 2018 and 2017	(205,999)	(205,999)
Accumulated deficit	(476,151,517)	(477,132,808)
Total stockholders' equity (deficit)	1,773,478	(26,567,598)
Total liabilities and stockholders' equity (deficit)	$ 19,621,088	$ 10,667,203

Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Accounts receivable, allowance	$ 300,510	$ 361,350
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares outstanding	23,900	23,900
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	59,044,164	22,805,731
Treasury stock, shares	4,015	4,015

Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
Statements of Operations (Unaudited) - USD ($)	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Revenue:
Systems	$ 715,484	$ 1,597,537	$ 1,043,510	$ 3,644,871
Disposables, service and accessories	6,839,995	6,546,198	21,035,002	19,943,562
Total revenue	7,555,479	8,143,735	22,078,512	23,588,433
Cost of revenue:
Systems	596,869	888,800	1,257,980	2,029,760
Disposables, service and accessories	1,036,589	1,032,569	3,029,875	3,350,480
Total cost of revenue	1,633,458	1,921,369	4,287,855	5,380,240
Gross margin	5,922,021	6,222,366	17,790,657	18,208,193
Operating expenses:
Research and development	2,000,780	1,619,749	5,995,800	4,976,892
Sales and marketing	2,819,101	3,079,562	9,911,514	10,479,626
General and administrative	1,215,920	1,355,258	3,753,703	4,921,513
Total operating expenses	6,035,801	6,054,569	19,661,017	20,378,031
Operating income (loss)	(113,780)	167,797	(1,870,360)	(2,169,838)
Other income (expense)		(4,459,042)	2,590,361	(1,029,479)
Interest expense (net)	(2,515)	(43,077)	(33,271)	(135,336)
Net income (loss)	(116,295)	(4,334,322)	686,730	(3,334,653)
Cumulative dividend on convertible preferred stock	(361,447)	(337,963)	(1,072,553)	(1,070,812)
Net loss attributable to common stockholders	$ (477,742)	$ (4,672,285)	$ (385,823)	$ (4,405,465)
Net loss per share attributable to common stockholders:
Basic	$ (0.01)	$ (0.21)	$ (0.01)	$ (0.20)
Diluted	$ (0.01)	$ (0.21)	$ (0.01)	$ (0.20)
Weighted average number of common shares and equivalents:
Basic	59,008,219	22,750,405	49,733,553	22,551,496
Diluted	59,008,219	22,750,405	49,733,553	22,551,496

Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
Statements of Cash Flows (Unaudited) - USD ($)	Sep. 30, 2018	Sep. 30, 2017
Cash flows from operating activities
Net income (loss)	$ 686,730	$ (3,334,653)
Adjustments to reconcile net income to cash used in operating activities:
Depreciation	394,154	412,793
Amortization of intangibles	49,491	149,491
Amortization of deferred finance costs	24,657	74,793
Share-based compensation	465,851	625,854
Loss on asset disposal	1,449	20,772
Adjustment of warrants	(2,590,361)	1,029,479
Changes in operating assets and liabilities:
Accounts receivable	(800,856)	617,873
Inventories	(55,486)	775,577
Prepaid expenses and other current assets	(131,116)	(46,427)
Other assets	(1,799)	(7,105)
Accounts payable	(80,066)	(889,868)
Accrued liabilities	(372,289)	(979,526)
Deferred revenue	553,937	(2,497,775)
Other liabilities	86,204	176,905
Net cash used in operating activities	(1,769,500)	(3,871,817)
Cash flows from investing activities
Purchase of fixed assets	(255,554)	(72,082)
Net cash used in investing activities	(255,554)	(72,082)
Cash flows from financing activities
Payments of deferred financing costs		(100,000)
Proceeds from issuance of stock, net of issuance costs	44,621	29,573
Proceeds from warrant exercise	9,864,697
Net cash provided by (used in) financing activities	9,909,318	(70,427)
Net increase (decrease) in cash and cash equivalents	7,884,264	(4,014,326)
Cash and cash equivalents at beginning of period	3,686,302	8,501,392
Cash and cash equivalents at end of period	$ 11,570,566	$ 4,487,066

Description of Business

9 Months Ended

Sep. 30, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Description of Business

1. Description of Business

Stereotaxis designs, manufactures and markets the Epoch Solution, which is an advanced remote robotic navigation system for use in a hospital’s interventional surgical suite, or “interventional lab”, that we believe revolutionizes the treatment of arrhythmias and coronary artery disease by enabling enhanced safety, efficiency, and efficacy for catheter-based, or interventional, procedures. The Epoch Solution is comprised of the Niobe ES Remote Magnetic Navigation System (“Niobe ES system”), Odyssey Information Management Solution (“Odyssey Solution”), and the Vdrive Robotic Navigation System (“Vdrive system”), and related devices.

The Niobe system is designed to enable physicians to complete more complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, efficient procedures, and reduced x-ray exposure. As of September 30, 2018, the Company had an installed base of 127 Niobe ES systems.

In addition to the Niobe system and its components, Stereotaxis also has developed the Odyssey Solution, which consolidates all lab information enabling doctors to focus on the patient for optimal procedure efficiency. The system also features a remote viewing and recording capability called Odyssey Cinema, which is an innovative solution delivering synchronized content for optimized workflow, advanced care, and improved productivity. This tool includes an archiving capability that allows clinicians to store and replay entire procedures or segments of procedures. This information can be accessed from locations throughout the hospital local area network and over the global Odyssey Network providing physicians with a tool for clinical collaboration, remote consultation, and training.

Our Vdrive system provides navigation and stability for diagnostic and therapeutic devices designed to improve interventional procedures. The Vdrive system complements the Niobe ES system control of therapeutic catheters for fully remote procedures and enables single-operator workflow and is sold as two options, the Vdrive system and the Vdrive Duo system. In addition to the Vdrive system and the Vdrive Duo system, we also manufacture and market various disposable components which can be manipulated by these systems.

We promote the full Epoch Solution in a typical hospital implementation, subject to regulatory approvals or clearances. The full Epoch Solution implementation requires a hospital to agree to an upfront capital payment and recurring payments. The upfront capital payment typically includes equipment and installation charges. The recurring payments typically include disposable costs for each procedure, equipment service costs beyond warranty period, and software licenses. In hospitals where the full Epoch Solution has not been implemented, equipment upgrade or expansion can be implemented upon purchasing of the necessary upgrade or expansion.

The core components of Stereotaxis systems, such as the Niobe System, Odyssey Workstation, Cardiodrive, and various disposable interventional devices have received regulatory clearance in the U.S., Europe, Canada, China, Japan and various other countries. We have received the regulatory clearance, licensing and/or CE Mark approvals that allow us to market the Vdrive and Vdrive Duo systems with the V-CAS, V-Loop and V-Sono devices in the U.S., Canada and European Union. The V-CAS Deflect catheter advancement system has been CE Marked for sale in the European Union.

We have successfully integrated our Niobe system with digital fluoroscopy systems to provide advanced interventional lab visualization and instrument control through user-friendly computerized interfaces. The maintenance of these arrangements, or the establishment of equivalent alternatives, is critical to our commercialization efforts. The commercial availability of both currently compatible digital imaging fluoroscopy systems is unlikely to continue for multiple years and efforts are being made to ensure the availability of integrated next generation systems and/or equivalent alternatives; however, we cannot provide assurance as to the timeline of the ongoing availability of such compatible systems or our ability to obtain equivalent alternatives on competitive terms or at all.

Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2018

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited financial statements of Stereotaxis, Inc. have been prepared in accordance with generally accepted accounting principles for interim financial information and the instructions to Form 10-Q. Accordingly, they do not include all the disclosures required by U.S. generally accepted accounting principles for complete financial statements. In the opinion of management, they include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods presented. Operating results for the nine month period ended September 30, 2018 are not necessarily indicative of the results that may be expected for the year ended December 31, 2018 or for future operating periods.

These interim financial statements and the related notes should be read in conjunction with the annual financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 as filed with the Securities and Exchange Commission (SEC) on March 20, 2018.

Going Concern, Liquidity and Management’s Plan

The Company believes the cash on hand at September 30, 2018 will be sufficient to meet its obligations as they become due in the ordinary course of business for at least 12 months following the date these financial statements are issued. The Company has sustained operating losses throughout its corporate history and expects that its 2018 expenses will exceed its 2018 gross margin. The Company expects to continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations or expense reductions are in place. The Company’s liquidity needs will be largely determined by the success of clinical adoption within the installed base of Niobe systems as well as by new placements of capital systems.

Financial Instruments

Financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, and debt. The carrying value of such amounts reported at the applicable balance sheet dates approximates fair value.

The Company measures certain financial assets and liabilities at fair value on a recurring basis. General accounting principles for fair value measurement established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (“Level 1”) and the lowest priority to unobservable inputs (“Level 3”). See Note 10 for additional details.

Revenue and Costs of Revenue

The Company adopted ASC 606, Revenue from Contracts with Customers, on January 1, 2018 using the modified retrospective method. As part of the Company's adoption of ASC 606, the Company elected to use the following practical expedients (i) applying the modified retrospective method only to open contracts as of December 31, 2017; (ii) not to adjust the promised amount of consideration for the effects of a significant financing component when the Company expects, at contract inception, that the period between the Company's transfer of a promised product or service to a customer and when the customer pays for that product or service will be one year or less; (iii) to expense costs as incurred for costs to obtain a contract when the amortization period would have been one year or less; and (iv) not to assess whether promised goods or services are performance obligations if they are immaterial in the context of the contract with the customer.

Upon adoption of the new revenue guidance, the Company recorded a cumulative-effect reduction to accumulated deficit of $0.3 million on January 1, 2018 relating primarily to the deferral of previously expensed costs to obtain a contract. The Company capitalized sales commissions paid in connection with multi-year service contracts and is amortizing such asset over the economic life of those contracts. Previously, sales commissions on multi-year service contracts were expensed as incurred. The impact of this change on operating expenses in any given period will depend, in part, on the amount of such commissions incurred and capitalized in relation to the amount of ongoing amortization expense. For the nine months ended September 30, 2018, the Company recorded less than $0.1 million in additional commission expense as a result of adopting the new standard. The Company did not otherwise experience significant changes in the timing or method of revenue recognition for any of its material revenue streams.

We generate revenue from initial capital sales of systems as well as recurring revenue from the sale of our proprietary disposable devices, from royalties paid to the Company on the sale by Biosense Webster of co-developed catheters, and from other recurring revenue including ongoing license and service contracts.

We account for a contract with a customer when there is a legally enforceable contract between the Company and the customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. We record our revenue based on consideration specified in the contract with each customer, net of any taxes collected from customers that are remitted to government authorities.

For contracts containing multiple products and services the Company accounts for individual products and services as separate performance obligations if they are distinct, which is if a product or service is separately identifiable from other items in the bundled package, and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The Company recognizes revenues as the performance obligations are satisfied by transferring control of the product or service to a customer.

For multiple-element arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or services. If a standalone selling price is not directly observable, then the Company estimates the standalone selling price considering market conditions and entity-specific factors including, but not limited to, features and functionality of the products and services and market conditions. The Company regularly reviews standalone selling prices and updates these estimates as necessary.

Systems:

Contracts related to the sale of systems typically contain separate obligations for the delivery of system(s), installation and an implied obligation to provide software enhancements if and when available for one year following installation. Revenue is recognized when the Company transfers control to the customer, which is generally at the point when acceptance occurs that indicates customer acknowledgment of delivery or installation, depending on the terms of the arrangement. Revenue from the implied obligation to deliver software enhancements if and when available is recognized ratably over the first year following installation of the system as the customer receives the right to software updates throughout the period and is included in Other Recurring Revenue. The Company’s system contracts generally do not provide a right of return. Systems are generally covered by a one-year assurance type warranty; warranty costs were not material for the periods presented. Revenue from system delivery and installation represented 5% and 15% of revenue for the nine months ended September 30, 2018 and 2017, respectively.

Disposables:

Revenue from sales of disposable products is recognized when control is transferred to the customers, which generally occurs at the time of shipment, but can also occur at the time of delivery depending on the customer arrangement. Disposable products are covered by an assurance type warranty that provides for the return of defective products. Warranty costs were not material for the periods presented. Disposable revenue represented 33% and 32% of revenue for the nine months ended September 30, 2018 and 2017, respectively.

Royalty:

The Company is entitled to royalty payments from Biosense Webster, payable quarterly based on net revenues from sales of the co-developed catheters. Royalty revenue from the co-developed catheters represented 10% and 9% of revenue for the nine months ended September 30, 2018 and 2017.

Other Recurring Revenue:

Other recurring revenue includes revenue from product maintenance plans, other post warranty maintenance, and the implied obligation to provide software enhancements if and when available for one year following installation. Revenue from services and software enhancements is deferred and amortized over the service or update period, which is typically one year. Revenue related to services performed on a time-and-materials basis is recognized when performed. Other recurring revenue represented 52% and 44% of revenue for the nine months ended September 30, 2018 and 2017, respectively.

	Three months ended September 30,				Nine Months Ended September 30,
	2018		2017		2018		2017
Systems	$	715,484	$	1,597,537	$	1,043,510	$	3,644,871
Disposables, service and accessories		6,839,995		6,546,198		21,035,002		19,943,562
Total revenue	$	7,555,479	$	8,143,735	$	22,078,512	$	23,588,433

Transaction price allocated to remaining performance obligations relates to amounts allocated to products and services for which the revenue has not yet been recognized. A significant portion of this amount relates to the Company's systems contracts and obligations that will be recognized as revenue in future periods. These obligations are generally satisfied within two years after contract inception but may occasionally extend longer. Transaction price representing revenue to be earned on remaining performance obligations on system contracts was approximately $1.0 million as of September 30, 2018. Performance obligations arising from contracts for disposables, royalty and service are generally expected to be satisfied within one year after entering into the contract.

The following information summarizes the Company’s contract assets and liabilities:

	September 30,			December 31,
	2018			2017
Contract Assets - Unbilled Receivables	$	139,973		$	2,917

Product shipped, revenue deferred		661,402			941,724
Deferred service and license fees		6,207,167			5,372,908
Total deferred revenue		6,868,569			6,314,632
Less: Long-term deferred revenue		(502,893	)		(611,863	)
Total current deferred revenue	$	6,365,676		$	5,702,769

The Company invoices its customers based on the billing schedules in its sales arrangements. Contract assets primarily represent the difference between the revenue that was earned but not billed on service contracts and revenue from system contracts that was recognized based on the relative selling price of the related performance obligations and the contractual billing terms in the arrangements. Deferred revenue is primarily related to service contracts, for which the service fees are billed up-front, generally quarterly or annually, and for amounts billed in advance for system contracts for which some performance obligations remain outstanding. For service contracts, the associated deferred revenue is generally recognized ratably over the service period. For system contracts, the associated deferred revenue is recognized when the remaining performance obligations are satisfied. The Company did not have any impairment losses on its contract assets for the periods presented.

Revenue recognized for the nine months ended September 30, 2018 and 2017, that was included in the deferred revenue balance at the beginning of each reporting period was $5,125,372 and $7,652,148, respectively.

Assets Recognized from the Costs to Obtain a Contract with a Customer

The Company has determined that sales incentive programs for the Company’s sales team meet the requirements to be capitalized as the Company expects to generate future economic benefits from the related revenue generating contracts after the initial capital sales transaction. The costs capitalized as contract acquisition costs included in prepaid expenses and other assets, in the Company’s balance sheet was $0.3 million as of September 30, 2018. The Company did not incur any impairment losses during any of the periods presented.

Costs of systems revenue include direct product costs, installation labor and other costs, estimated warranty costs, and initial training and product maintenance costs. These costs are recorded at the time of sale. Costs of disposable revenue include direct product costs and estimated warranty costs and are recorded at the time of sale. Cost of revenue from services and license fees are recorded when incurred.

Share-Based Compensation

The Company accounts for its grants of stock options, stock appreciation rights, restricted shares, and restricted stock units and for its employee stock purchase plan in accordance with the provisions of general accounting principles for share-based payments. These accounting principles require the determination of the fair value of the share-based compensation at the grant date and the recognition of the related expense over the period in which the share-based compensation vests.

The Company utilizes the Black-Scholes valuation model to determine the fair value of stock options and stock appreciation rights at the date of grant. The resulting compensation expense is recognized over the requisite service period, which is generally four years. Restricted shares granted to employees are valued at the fair market value at the date of grant. The Company amortizes the fair market value to expense over the service period. If the shares are subject to performance objectives, the resulting compensation expense is amortized over the anticipated vesting period and is subject to adjustment based on the actual achievement of objectives.

Net Income (Loss) per Common Share (“EPS”)

Basic net income (loss) per share is computed by dividing net income (loss) attributable to common shareholders by the number of common shares outstanding during the period. In periods where there is net income, we apply the two-class method to calculate basic and diluted net income (loss) per share of common stock, as our Convertible Preferred Stock is a participating security. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to common stockholders. In periods where there is a net loss, the two-class method of computing earnings per share does not apply as our Convertible Preferred Stock does not contractually participate in our losses. We compute diluted net income (loss) per common share using net income (loss) as the “control number” in determining whether potential common shares are dilutive, after giving consideration to all potentially dilutive common shares, including stock options, warrants, unvested restricted stock units outstanding during the period and potential issuance of stock upon the conversion of our Convertible Preferred Stock issued and outstanding during the period, except where the effect of such securities would be antidilutive.

The following table sets forth the computation of basic and diluted EPS:

	Three months ended September 30,						Nine Months Ended September 30,
	2018			2017			2018			2017
Net income (loss)	$	(116,295	)	$	(4,334,322	)	$	686,730		$	(3,334,653	)
Cumulative dividend on convertible preferred stock		(361,447	)		(337,963	)		(1,072,553	)		(1,070,812	)
Net loss attributable to common stockholders	$	(477,742	)	$	(4,672,285	)	$	(385,823	)	$	(4,405,465	)
Weighted average number of common shares and equivalents:		59,008,219			22,750,405			49,733,553			22,551,496
Basic EPS	$	(0.01	)	$	(0.21	)	$	(0.01	)	$	(0.20	)
Diluted EPS	$	(0.01	)	$	(0.21	)	$	(0.01	)	$	(0.20	)

The Company did not include any portion of unearned restricted stock units, outstanding options, stock appreciation rights, or warrants in the calculation of diluted loss per common share because all such securities are anti-dilutive for all periods presented.

As of September 30, 2018, the Company had 1,154,325 shares of common stock issuable upon the exercise of outstanding options and stock appreciation rights at a weighted average exercise price of $2.80 per share, 2,280,364 shares of common stock issuable upon the exercise of outstanding warrants at a weighted average exercise price of $2.04 per share, 41,187,582 shares of common stock issuable upon the conversion of Series A Convertible Preferred Stock and accumulated dividends, and 653,399 shares of unvested restricted share units.

Reclassifications

In 2018, we adjusted our operating expense categories to improve our alignment with common industry reporting practice, and as a result, certain amounts in prior periods have been reclassified to conform to the current period presentation. For the nine months ended September 30, 2017, approximately $1.4 million of regulatory and clinical research expenses previously included in General and Administrative expense have been reclassified to Research and Development expense, and approximately $0.4 million of international training expense previously included in General and Administrative expense has been reclassified to Sales and Marketing expense. These reclassifications had no effect on reported income or losses.

Recently Issued Accounting Pronouncements

In February 2016, the FASB issued ASU 2016-02, “Leases (ASC 842),” which sets out the principles for the recognition, measurement, presentation, and disclosure of leases for both parties to a contract (i.e. lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. ASC 842 supersedes the previous leases standard, ASC 840 Leases. The standard is effective for interim and annual periods beginning after December 31, 2018 (January 1, 2019 for the Company), with early adoption permitted. The Company is in the process of evaluating the impact of this accounting standard update.

Convertible Preferred Stock and Stockholders' Equity

9 Months Ended

Sep. 30, 2018

Stockholders' Equity Note [Abstract]

Convertible Preferred Stock and Stockholders' Equity

9. Convertible Preferred Stock and Stockholders’ Equity

The holders of common stock are entitled to one vote for each share held and to receive dividends whenever funds are legally available and when declared by the Board of Directors subject to the rights of holders of all classes of stock having priority rights as dividends and the conditions of the revolving line of credit agreement. No dividends have been declared or paid as of September 30, 2018.

Convertible Preferred Stock and Warrants

In September 2016, the Company issued 24,000 shares of Series A Convertible Preferred Stock, par value $0.001 with a stated value of $1,000 per share which are convertible into shares of the Company’s common stock at an initial conversion rate of $0.65 per share and (ii) warrants to purchase an aggregate of 36,923,078 shares of common stock. The convertible preferred shares are entitled to vote on an as-converted basis with the common stock, subject to specified beneficial ownership issuance limitations. The convertible preferred shares bear dividends at a rate of six percent (6%) per annum, which are cumulative and accrue daily from the date of issuance on the $1,000 stated value. Such dividends will not be paid in cash except in connection with any liquidation, dissolution or winding up of the Company or any redemption of the convertible preferred shares. Each holder of convertible preferred shares has the right to require us to redeem such holder’s convertible preferred shares upon the occurrence of specified events, which include certain business combinations, the sale of all or substantially all of the Company’s assets, or the sale of more than 50% of the outstanding shares of the Company’s common stock. In addition, the Company has the right to redeem the convertible preferred shares in the event of a defined change of control. The convertible preferred shares rank senior to our common stock as to distributions and payments upon the liquidation, dissolution, and winding up of the Company. Since the convertible preferred shares are subject to conditions for redemption that are outside the Company’s control, the convertible preferred shares are presently reported in the mezzanine section of the balance sheet.

The warrants issued in conjunction with the convertible preferred stock have an exercise price equal to $0.70 per share subject to adjustments as provided under the terms of the warrants. The warrants are exercisable through September 29, 2021, subject to specified beneficial ownership issuance limitations. Prior to their modification in February 2018, the warrants were puttable upon the occurrence of certain events outside of the Company’s control, and were classified as liabilities under ASC 480-10. The calculated fair value of the warrants was periodically re-measured with any changes in value recognized in “Other income (expense)” in the Statements of Operations. See Note 10 for additional details.

The warrants were modified on February 28, 2018 to allow for a reduction in the exercise price from $0.70 per share to $0.28 per share for a period between March 1, 2018 and March 5, 2018. Additionally, the beneficial ownership limitation related to the warrants was modified and the right of holders to require the Company to redeem their SPA Warrants in exchange for cash in certain circumstances was eliminated. Following these modifications, the warrants were no longer subject to liability accounting and were reclassified to equity. During the restricted exercise period, Stereotaxis received exercise notices for 35,791,927 warrants and received an aggregate of $10.0 million in cash from the warrant exercise. As a result of these transactions, total stockholders’ equity increased by $27 million and common shares outstanding increased by 35,791,927 shares.

Stock Award Plans

The Company has various stock plans that permit the Company to provide incentives to employees and directors of the Company in the form of equity compensation. In July 2012, the Compensation Committee of the Board of Directors adopted the 2012 Stock Incentive Plan (the “Plan”) which was subsequently approved by the Company’s shareholders. This plan replaced the 2002 Stock Incentive Plan which expired on March 25, 2012.

On June 5, 2013, June 10, 2014, May 24, 2016, and May 23, 2017, the shareholders approved amendments to the Plan, which were previously approved and adopted by the Compensation Committee of the Board of Directors of the Company. Under each of the amendments on June 5, 2013 and June 10, 2014, the number of shares authorized for issuance under the Plan was increased by one million shares. The amendment on May 24, 2016 increased the number of shares authorized for issuance under the Plan by 1.5 million shares, and the amendment on May 23, 2017 increased the number of shares authorized for issuance under the Plan by 4.0 million shares. At September 30, 2018, the Company had 4,453,764 remaining shares of the Company’s common stock to provide for current and future grants under its various equity plans.

At September 30, 2018, the total compensation cost related to options, stock appreciation rights, and non-vested stock granted to employees under the Company’s stock award plans but not yet recognized was approximately $0.8 million. This cost will be amortized over a period of up to four years over the underlying estimated service periods and will be adjusted for subsequent changes in actual forfeitures and anticipated vesting periods.

A summary of the option and stock appreciation rights activity for the nine month period ended September 30, 2018 is as follows:

	Number of Options/SARs			Range of Exercise Price	Weighted Average Exercise Price per Share

Outstanding, December 31, 2017		413,301		$0.62 - $54.90	$	9.04
Granted		902,500		$0.74 - $0.83	$	0.75
Exercised		(2,916	)	$0.62	$	0.62
Forfeited		(158,560	)	$0.62 - $54.90	$	7.41
Outstanding, September 30, 2018		1,154,325		$0.62 - $43.90	$	2.80

A summary of the restricted stock unit activity for the nine month period ended September 30, 2018 is as follows:

	Number of Restricted Stock Units			Weighted Average Grant Date Fair Value per Unit

Outstanding, December 31, 2017		680,363		$	1.11
Granted		422,167		$	0.80
Vested		(382,356	)	$	1.24
Forfeited		(66,775	)	$	1.12
Outstanding, September 30, 2018		653,399		$	0.84

Fair Value Measurements

9 Months Ended

Sep. 30, 2018

Fair Value Disclosures [Abstract]

Fair Value Measurements

10. Fair Value Measurements

The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents and warrants. General accounting principles for fair value measurement established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (“Level 1”) and the lowest priority to unobservable inputs (“Level 3”). The three levels of the fair value hierarchy are described below:

	Level 1:	Values are based on unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

	Level 2:	Values are based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or other model-based valuation techniques for which all significant assumptions are observable in the market.

	Level 3:	Values are generated from model-based techniques that use significant assumptions not observable in the market.

The following table sets forth the Company’s assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy. As required by the Fair Value Measurements and Disclosures topic of the Accounting Standards Codification, assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.

	Fair Value Measurement Using
	Total		Quoted Prices in Active Markets for Identical Instruments (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Liabilities at September 30, 2018:
Warrants issued August 2013	$	—	$	—	$	—	$	—
Warrants issued September 2016		—		—		—		—
Total liabilities at fair value:	$	—	$	—	$	—	$	—
Liabilities at December 31, 2017:
Warrants issued August 2013	$	5,746	$	—	$	—	$	5,746
Warrants issued September 2016		19,569,231		—		—		19,569,231
Total liabilities at fair value:	$	19,574,977	$	—	$	—	$	19,574,977

Level 1

The Company does not have any material financial assets or liabilities classified as Level 1.

Level 2

The Company does not have any financial assets or liabilities classified as Level 2.

Level 3

In conjunction with the Company’s August 2013 and September 2016 financing transactions, the Company issued warrants to purchase shares of the Company’s common stock. Due to the provisions included in the warrant agreements at the time of issuance, the warrants did not meet the exemptions for equity classification and as such, the Company accounted for these warrants as derivative instruments. The calculated fair value of the warrants issued in conjunction with the August 2013 financing transactions is classified as a liability and is periodically re-measured with any changes in value recognized in “Other income (expense)” in the Statements of Operations. As detailed in Note 9, the remaining warrants from the September 2016 transaction were modified on February 28, 2018 and reclassified to equity.

The remaining warrants from the August 2013 transaction (Exchange Warrants) expire in November 2018 and were revalued as of September 30, 2018 using the following assumptions: 1) volatility of 70.17%; 2) risk-free interest rate of 2.19%; and 3) a closing stock price of $1.21.

The significant unobservable input used in the fair value measurement of the Company’s warrants is volatility. Significant increases (decreases) in the volatility in isolation would result in significantly higher (lower) liability fair value measurements.

The following table sets forth a summary of changes in the fair value of the Company’s Level 3 financial liabilities for the nine month period ended September 30, 2018:

	Warrants issued August 2013			Warrants issued September 2016			Total Liabilities
Balance at beginning of period	$	5,746		$	19,569,231		$	19,574,977
Issues		-			-			-
Reclassifications		-			(16,984,616	)		(16,984,616	)
Settlements		-			-			-
Revaluation		(5,746	)		(2,584,615	)		(2,590,361	)
Balance at end of period	$	-		$	-		$	-

The Company currently does not have derivative instruments to manage its exposure to currency fluctuations or other business risks. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. All derivative financial instruments are recognized in the balance sheet at fair value.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2018

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

Going Concern, Liquidity and Management's Plan

Going Concern, Liquidity and Management’s Plan

Financial Instruments

Financial Instruments

Revenue and Costs of Revenue

Revenue and Costs of Revenue

Systems:

Disposables:

Royalty:

Other Recurring Revenue:

	Three months ended September 30,				Nine Months Ended September 30,
	2018		2017		2018		2017
Systems	$	715,484	$	1,597,537	$	1,043,510	$	3,644,871
Disposables, service and accessories		6,839,995		6,546,198		21,035,002		19,943,562
Total revenue	$	7,555,479	$	8,143,735	$	22,078,512	$	23,588,433

The following information summarizes the Company’s contract assets and liabilities:

	September 30,			December 31,
	2018			2017
Contract Assets - Unbilled Receivables	$	139,973		$	2,917

Product shipped, revenue deferred		661,402			941,724
Deferred service and license fees		6,207,167			5,372,908
Total deferred revenue		6,868,569			6,314,632
Less: Long-term deferred revenue		(502,893	)		(611,863	)
Total current deferred revenue	$	6,365,676		$	5,702,769

Assets Recognized from the Cost to Obtain a Contract with a Customer

Assets Recognized from the Costs to Obtain a Contract with a Customer

Share-based Compensation

Share-Based Compensation

Net Income (Loss) per Common Share ("EPS")

Net Income (Loss) per Common Share (“EPS”)

The following table sets forth the computation of basic and diluted EPS:

	Three months ended September 30,						Nine Months Ended September 30,
	2018			2017			2018			2017
Net income (loss)	$	(116,295	)	$	(4,334,322	)	$	686,730		$	(3,334,653	)
Cumulative dividend on convertible preferred stock		(361,447	)		(337,963	)		(1,072,553	)		(1,070,812	)
Net loss attributable to common stockholders	$	(477,742	)	$	(4,672,285	)	$	(385,823	)	$	(4,405,465	)
Weighted average number of common shares and equivalents:		59,008,219			22,750,405			49,733,553			22,551,496
Basic EPS	$	(0.01	)	$	(0.21	)	$	(0.01	)	$	(0.20	)
Diluted EPS	$	(0.01	)	$	(0.21	)	$	(0.01	)	$	(0.20	)

Reclassifications

Reclassifications

Recently Issued Accounting Pronouncements

Recently Issued Accounting Pronouncements

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Mar. 05, 2018	Jan. 02, 2018	Dec. 31, 2017
Effect on accumulated deficit				$ 300,000
Remaining performance obligation	$ 1,000,000
Revenue recognized	5,125,372	$ 7,652,148
Capitalized contract costs	$ 300,000
Options and stock appreciation rights	1,154,325				413,301
Weighted average exercise price	$ 2.80				$ 9.04
Exercise price of warrants	$ 0.70
Research and Development Expense [Member]
Reclassification amount		1,400,000
Selling and Marketing Expense [Member]
Reclassification amount		$ 400,000
Stock Option [Member]
Options and stock appreciation rights	1,154,325
Weighted average exercise price	$ 2.80
Warrant [Member]
Common stock issuable upon exercise, warrants	2,280,364
Exercise price of warrants	$ 2.04
Series A Convertible Preferred Stock [Member]
Options and stock appreciation rights	41,187,582
Restricted Stock Units [Member]
Unvested restricted shares	653,399
Revenue from System Delivery and Installation [Member]
Revenues percentage	5.00%	15.00%
Disposable Revenue [Member]
Revenues percentage	33.00%	32.00%
Royalty Revenue [Member]
Revenues percentage	10.00%	9.00%
Other Recurring Revenue [Member]
Revenues percentage	52.00%	44.00%
Maximum [Member]
Effect on income	$ 100,000
Exercise price of warrants			$ 0.70

Summary of Significant Accounting Policies - Computation of Basic and Diluted Earnings Per Share (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Accounting Policies [Abstract]
Net income (loss)	$ (116,295)	$ (4,334,322)	$ 686,730	$ (3,334,653)
Cumulative dividend on convertible preferred stock	(361,447)	(337,963)	(1,072,553)	(1,070,812)
Net loss attributable to common stockholders	$ (477,742)	$ (4,672,285)	$ (385,823)	$ (4,405,465)
Weighted average number of common shares and equivalents:	59,008,219	22,750,405	49,733,553	22,551,496
Basic EPS	$ (0.01)	$ (0.21)	$ (0.01)	$ (0.20)
Diluted EPS	$ (0.01)	$ (0.21)	$ (0.01)	$ (0.20)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Prepaid Expenses and Other Assets - Schedule of Prepaid Expenses and Other Assets (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid expenses	$ 311,021	$ 575,501
Prepaid commissions	333,940
Deferred financing costs		24,658
Deposits	552,375	194,358
Total prepaid expenses and other assets	1,197,336	794,517
Less: Noncurrent prepaid expenses and other assets	(226,939)	(44,432)
Total current prepaid expenses and other assets	$ 970,397	$ 750,085

Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017	Dec. 31, 2016	Sep. 30, 2013
Payables and Accruals [Abstract]
Accrued salaries, bonus, and benefits	$ 1,466,306	$ 1,641,491
Accrued rent	162,896	441,417		$ 515,138
Accrued licenses and maintenance fees	578,409	581,672
Accrued warranties	148,290	164,365	$ 222,845
Accrued taxes	272,498	234,668
Accrued professional services	494,242	367,072
Other	321,890	299,931
Total accrued liabilities	3,444,531	3,730,616
Less: Long term accrued liabilities	(621,573)	(535,369)
Total current accrued liabilities	$ 2,822,958	$ 3,195,247

Long-Term Debt and Credit Facilities (Details Narrative)	Apr. 26, 2018 USD ($)	Apr. 26, 2018 USD ($)	Sep. 30, 2018 USD ($)	Dec. 31, 2017 USD ($)
Debt Instrument [Line Items]
Total liquidity			$ 14,800,000
Cash and cash equivalents			11,570,566	$ 3,686,302
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity	$ 5,000,000	$ 5,000,000	5,000,000
Line of credit extended date, description	On April 26, 2018, the Company entered into a First Amendment to Third Amended and Restated Loan and Security Agreement with Silicon Valley Bank to extend the maturity of the revolving line of credit to April 25, 2019.
Liquidity ratio	1.75	1.75
Minimum unrestricted cash balance			1,500,000
Line of credit facility, current borrowing capacity			$ 3,200,000
Revolving Credit Facility [Member] \| Prime Rate [Member] \| Streamline Period [Member]
Debt Instrument [Line Items]
Line of credit interest rate	4.50%
Revolving Credit Facility [Member] \| Prime Rate [Member] \| Non-Streamline Period [Member]
Debt Instrument [Line Items]
Line of credit interest rate	1.50%	4.50%

Convertible Preferred Stock and Stockholders' Equity (Details Narrative)						9 Months Ended
	May 23, 2017 shares	Sep. 30, 2016 USD ($) $ / shares shares	May 24, 2016 shares	Jun. 10, 2014 shares	Jun. 05, 2013 shares	Sep. 30, 2018 USD ($) Integer $ / shares shares	Sep. 30, 2017 USD ($)	Mar. 05, 2018 $ / shares	Dec. 31, 2017 $ / shares
Number of stockholders votes \| Integer						1
Dividends declared \| $
Dividends paid \| $
Preferred stock, par value \| $ / shares						$ 0.001			$ 0.001
Preferred stock redemption, triggering event, percent of common stock sold threshold		50.00%
Exercise price of warrants \| $ / shares						$ 0.70
Warrants exercisable date						Sep. 29, 2021
Proceeds from warrants exercises \| $						$ 9,864,697
Increased in stockholders' equity \| $						$ 27,000,000
Increased in common shares outstanding \| shares						35,791,927
Remaining shares available for issuance \| shares						4,453,764
Total compensation cost not yet recognized \| $						$ 800,000
Weighted average amortization period of total compensation cost not yet recognized						4 years
2012 Stock Incentive Plan [Member]
Stock plan expiration date						Mar. 25, 2012
Increase in number of shares authorized for issuance under the plan \| shares	4,000,000		1,500,000	1,000,000	1,000,000
Maximum [Member]
Exercise price of warrants \| $ / shares								$ 0.70
Minimum [Member]
Exercise price of warrants \| $ / shares								$ 0.28
Series A Convertible Preferred Stock [Member]
Number of preferred stock issued \| shares		24,000
Preferred stock, par value \| $ / shares		$ 0.001
Preferred stock, stated value \| $		$ 1,000
Preferred stock, conversion price \| $ / shares		$ 0.65
Common stock issuable from warrants \| shares		36,923,078
Preferred stock dividend rate		6.00%

Convertible Preferred Stock and Stockholders' Equity - Summary of Option and Stock Appreciation Rights Activity (Details)	9 Months Ended
	Sep. 30, 2018 $ / shares shares
Number of Options/SARs, Outstanding, Beginning Balance \| shares	413,301
Number of Options/SARs, Granted \| shares	902,500
Number of Options/SARs, Exercised \| shares	(2,916)
Number of Options/SARs, Forfeited \| shares	(158,560)
Number of Options/SARs, Outstanding, Ending Balance \| shares	1,154,325
Weighted Average Exercise Price per Share, Outstanding, Beginning Balance	$ 9.04
Weighted Average Exercise Price per Share, Granted	0.75
Weighted Average Exercise Price per Share, Exercised	0.62
Weighted Average Exercise Price per Share, Forfeited	7.41
Weighted Average Exercise Price per Share, Outstanding, Ending Balance	2.80
Range One [Member]
Range of Exercise Price, Lower Limit	0.62
Range of Exercise Price, Upper Limit	54.90
Range Two [Member]
Range of Exercise Price, Lower Limit	0.74
Range of Exercise Price, Upper Limit	0.83
Range Three [Member]
Range of Exercise Price, Upper Limit	0.62
Range Four [Member]
Range of Exercise Price, Lower Limit	0.62
Range of Exercise Price, Upper Limit	54.90
Range Five [Member]
Range of Exercise Price, Lower Limit	0.62
Range of Exercise Price, Upper Limit	$ 43.90

Convertible Preferred Stock and Stockholders' Equity - Summary of Restricted Stock Unit Activity (Details) - Restricted Stock Units [Member]	9 Months Ended
	Sep. 30, 2018 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Restricted Stock Units, Outstanding, December 31, 2017 \| shares	680,363
Number of Restricted Stock Units, Granted \| shares	422,167
Number of Restricted Stock Units, Vested \| shares	(382,356)
Number of Restricted Stock Units, Forfeited \| shares	(66,775)
Number of Restricted Stock Units, Outstanding, September 30, 2018 \| shares	653,399
Weighted Average Grant Date Fair Value per Unit, Outstanding, December 31, 2017 \| $ / shares	$ 1.11
Weighted Average Grant Date Fair Value per Unit, Granted \| $ / shares	0.80
Weighted Average Grant Date Fair Value per Unit, Vested \| $ / shares	1.24
Weighted Average Grant Date Fair Value per Unit, Forfeited \| $ / shares	1.12
Weighted Average Grant Date Fair Value per Unit, Outstanding, June 30, 2018 \| $ / shares	$ 0.84

Inventories - Schedule of Inventories (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Raw materials	$ 2,708,752	$ 2,528,270
Work in process	51,341	4,836
Finished goods	3,012,800	2,515,637
Reserve for obsolescence	(4,570,436)	(3,901,772)
Total inventory	$ 1,202,457	$ 1,146,971

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Gross property and equipment	$ 9,431,722	$ 9,888,037
Less: Accumulated depreciation	(8,979,083)	(9,295,349)
Net property and equipment	452,639	592,688
Equipment [Member]
Gross property and equipment	6,839,384	7,295,698
Leasehold Improvements [Member]
Gross property and equipment	$ 2,592,338	$ 2,592,339

Intangible Assets (Details Narrative)	Sep. 30, 2018 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Total intangible assets	$ 3,143,291
Accumulated amortization	$ 3,033,312

Accrued Liabilities (Details Narrative)	Sep. 30, 2018 USD ($) ft²	Dec. 31, 2017 USD ($)	Jan. 31, 2017 USD ($) ft²	Aug. 31, 2016 ft²	Sep. 30, 2013 USD ($) ft²
Real Estate [Line Items]
Accrued costs of rent liability \| $	$ 162,896	$ 441,417			$ 515,138
Accrued lease termination costs remaining \| $	$ 23,864
Office [Member]
Real Estate [Line Items]
Square feet of leased space \| ft²	52,000
Demonstration And Assembly [Member]
Real Estate [Line Items]
Square feet of leased space \| ft²	12,000
Unimproved Space [Member]
Real Estate [Line Items]
Square feet of leased space \| ft²					13,000
Office Sublease [Member]
Real Estate [Line Items]
Square feet of leased space \| ft²			16,000	11,000
Accrued costs of rent liability \| $			$ 69,180
Accrued lease termination costs remaining \| $	$ 6,723

Fair Value Measurements (Details Narrative) - Exchange Warrants [Member]	9 Months Ended
	Sep. 30, 2018 $ / shares
Warrant expiration date, description	November 2018
Closing stock price	$ 1.21
Measurement Input, Price Volatility [Member]
Fair value assumptions, measurement input, percentages	70.17%
Measurement Input, Risk Free Interest Rate [Member]
Fair value assumptions, measurement input, percentages	2.19%

Summary of Significant Accounting Policies - Summary of Contract Assets and Liabilities (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Total deferred revenue	$ 6,868,569	$ 6,314,632
Less: Long-term deferred revenue	(502,893)	(611,863)
Total current deferred revenue	6,365,676	5,702,769
Contract Assets - Unbilled Receivables [Member]
Total deferred revenue	139,973	2,917
Product Shipped, Revenue Deferred [Member]
Total deferred revenue	661,402	941,724
Deferred Service and License Fees [Member]
Total deferred revenue	$ 6,207,167	$ 5,372,908

Fair Value Measurements - Schedule of Assets And Liabilities Measured at Fair Value On Recurring Basis By Level (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Warrants issued		$ 19,574,977
Fair Value, Inputs, Level 1 [Member]
Total liabilities at fair value
Fair Value, Inputs, Level 2 [Member]
Total liabilities at fair value
Fair Value, Inputs, Level 3 [Member]
Total liabilities at fair value		19,574,977
Fair Value, Measurements, Recurring [Member]
Total liabilities at fair value		19,574,977
Fair Value, Measurements, Recurring [Member] \| Warrants Issued August 2013 [Member]
Warrants issued		5,746
Fair Value, Measurements, Recurring [Member] \| Warrants Issued August 2013 [Member] \| Fair Value, Inputs, Level 1 [Member]
Warrants issued
Fair Value, Measurements, Recurring [Member] \| Warrants Issued August 2013 [Member] \| Fair Value, Inputs, Level 2 [Member]
Warrants issued
Fair Value, Measurements, Recurring [Member] \| Warrants Issued August 2013 [Member] \| Fair Value, Inputs, Level 3 [Member]
Warrants issued		5,746
Fair Value, Measurements, Recurring [Member] \| Warrants Issued September 2016 [Member]
Warrants issued		19,569,231
Fair Value, Measurements, Recurring [Member] \| Warrants Issued September 2016 [Member] \| Fair Value, Inputs, Level 1 [Member]
Warrants issued
Fair Value, Measurements, Recurring [Member] \| Warrants Issued September 2016 [Member] \| Fair Value, Inputs, Level 2 [Member]
Warrants issued
Fair Value, Measurements, Recurring [Member] \| Warrants Issued September 2016 [Member] \| Fair Value, Inputs, Level 3 [Member]
Warrants issued		$ 19,569,231

Product Warranty Provisions (Details Narrative)	9 Months Ended
Product Warranty Provisions (Details Narrative)	Sep. 30, 2018
Product Warranties Disclosures [Abstract]
Standard product warranty coverage term	1 year